It’s been a rollercoaster ride for the Biotron Limited [ASX:BIT] share price, with the stock up 14.82% today, trading at $.155 at time of writing.
Reasons for the current volatility are hard to pin down, but profit-taking and new data released by the company could be factors.
The Biotron share price is down from a high of $.445 on 17 October, 2018:
Investors digesting new data from Biotron
For those of you with a biochemistry degree, the data can be found below:
Some highlights from the data include, a higher incidence of some side effects against placebo. These include headache, pyrexia (elevated body temperature), rash and rhinorrhoea (runny nose).
Additional quotes from the data include:
‘The BIT225 cohort had a significantly greater reduction of macrophage activation marker sCD163, a good indicator of all cause morbidity and mortality in HIV-2 patients. Additional reduction of this marker in patients taking BIT225 demonstrates significant immunological benefit.’
‘The stimulation of the immune system in the BIT225 cohort makes this treatment approach a unique and potentially clinical beneficial step towards HIV-1 eradication.’
Statistically significant results
As for the data itself, there were a number of statistically significant decreases for biomarker sCD163, statistically significant CD8* response, and statistically significant sustained delay in decline of CD4*.
To conclude, it is worth stressing that this is a Phase 2 trial, and the researchers are still trying to understand their own medicine.
Investors will be hoping ongoing investigations prove positive.
For Money Morning
PS: Learn how to pick the best bio-tech stocks with our free report. The download is available right here.